These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 18024887)

  • 1. Predicting the risk of pancreatic cancer: on CDKN2A mutations in the melanoma-pancreatic cancer syndrome in Italy.
    Ghiorzo P; Gargiulo S; Nasti S; Pastorino L; Battistuzzi L; Bruno W; Bonelli L; Taveggia P; Pugliese V; Borgonovo G; Mastracci L; Fornarini G; Romagnoli P; Iiritano E; Savarino V; Bianchi-Scarrà G
    J Clin Oncol; 2007 Nov; 25(33):5336-7; author reply 5337-8. PubMed ID: 18024887
    [No Abstract]   [Full Text] [Related]  

  • 2. Familial melanoma, pancreatic cancer and germline CDKN2A mutations.
    Goldstein AM
    Hum Mutat; 2004 Jun; 23(6):630. PubMed ID: 15146471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Germline mutations in CDKN2A are infrequent in female patients with melanoma and breast cancer.
    Nagore E; Montoro A; García-Casado Z; Botella-Estrada R; Insa A; Lluch A; López-Guerrero JA; Guillén C
    Melanoma Res; 2009 Aug; 19(4):211-4. PubMed ID: 19571771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case 7-2004: hereditary melanoma and pancreatic cancer.
    Koopmann J; Goggins M; Hruban RH
    N Engl J Med; 2004 Jun; 350(25):2623-4; author reply 2623-4. PubMed ID: 15201425
    [No Abstract]   [Full Text] [Related]  

  • 5. Five novel somatic CDKN2/p16 mutations identified in melanoma, glioma and carcinoma of the pancreas. Mutations in brief no. 170. Online.
    Gretarsdóttir S; Olafsdóttir GH; Borg A
    Hum Mutat; 1998; 12(3):212. PubMed ID: 10651484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the neoplastic phenotype in the familial atypical multiple-mole melanoma-pancreatic carcinoma syndrome.
    Rulyak SJ; Brentnall TA; Lynch HT; Austin MA
    Cancer; 2003 Aug; 98(4):798-804. PubMed ID: 12910525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Familial pancreatic cancer: from genes to improved patient care.
    Hruban RH; Klein AP; Eshleman JR; Axilbund JE; Goggins M
    Expert Rev Gastroenterol Hepatol; 2007 Oct; 1(1):81-8. PubMed ID: 19072437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pancreatic carcinoma surveillance in patients with familial melanoma.
    Parker JF; Florell SR; Alexander A; DiSario JA; Shami PJ; Leachman SA
    Arch Dermatol; 2003 Aug; 139(8):1019-25. PubMed ID: 12925390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The p.G23S CDKN2A founder mutation in high-risk melanoma families from Central Italy.
    Gensini F; Sestini R; Piazzini M; Vignoli M; Chiarugi A; Brandani P; Ghiorzo P; Salvini C; Borgognoni L; Palli D; Bianchi-Scarrà G; Carli P; Genuardi M
    Melanoma Res; 2007 Dec; 17(6):387-92. PubMed ID: 17992122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel type of deletion in the CDKN2A gene identified in a melanoma-prone family.
    Knappskog S; Geisler J; Arnesen T; Lillehaug JR; Lønning PE
    Genes Chromosomes Cancer; 2006 Dec; 45(12):1155-63. PubMed ID: 17001621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneity of risk for melanoma and pancreatic and digestive malignancies: a melanoma case-control study.
    Rutter JL; Bromley CM; Goldstein AM; Elder DE; Holly EA; Guerry D; Hartge P; Struewing JP; Hogg D; Halpern A; Sagebiel RW; Tucker MA
    Cancer; 2004 Dec; 101(12):2809-16. PubMed ID: 15529312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple melanomas after treatment for Hodgkin lymphoma in a non-Dutch p16-Leiden mutation carrier with 2 MC1R high-risk variants.
    Figl A; Thirumaran RK; Ugurel S; Gast A; Hemminki K; Kumar R; Schadendorf D
    Arch Dermatol; 2007 Apr; 143(4):495-9. PubMed ID: 17438182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of E27X, a novel CDKN2A germ line mutation, on p16 and p14ARF expression in Italian melanoma families displaying pancreatic cancer and neuroblastoma.
    Ghiorzo P; Gargiulo S; Pastorino L; Nasti S; Cusano R; Bruno W; Gliori S; Sertoli MR; Burroni A; Savarino V; Gensini F; Sestini R; Queirolo P; Goldstein AM; Scarrà GB
    Hum Mol Genet; 2006 Sep; 15(18):2682-9. PubMed ID: 16893909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDKN2A germline mutations in familial pancreatic cancer.
    Bartsch DK; Sina-Frey M; Lang S; Wild A; Gerdes B; Barth P; Kress R; Grützmann R; Colombo-Benkmann M; Ziegler A; Hahn SA; Rothmund M; Rieder H
    Ann Surg; 2002 Dec; 236(6):730-7. PubMed ID: 12454511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDKN2A mutations in Scottish families with cutaneous melanoma: results from 32 newly identified families.
    Lang J; Boxer M; MacKie RM
    Br J Dermatol; 2005 Dec; 153(6):1121-5. PubMed ID: 16307646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low prevalence of CDKN2A/ARF mutations among early-onset cancers of breast, pancreas and malignant melanoma in Poland.
    Debniak T; van de Wetering T; Scott R; Nagay L; Cybulski C; Górski B; Jakubowska A; Gronwald J; Masojć B; Huzarski T; Byrski T; Nej-Wołosiak K; Kładny J; Maleszka R; Lubinski J
    Eur J Cancer Prev; 2008 Oct; 17(5):389-91. PubMed ID: 18714178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A common founder for the V126D CDKN2A mutation in seven North American melanoma-prone families.
    Goldstein AM; Liu L; Shennan MG; Hogg D; Tucker MA; Struewing JP
    Br J Cancer; 2001 Aug; 85(4):527-30. PubMed ID: 11506491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New founder germline mutations of CDKN2A in melanoma-prone families and multiple primary melanoma development in a patient receiving levodopa treatment.
    Kannengiesser C; Dalle S; Leccia MT; Avril MF; Bonadona V; Chompret A; Lasset C; Leroux D; Thomas L; Lesueur F; Lenoir G; Sarasin A; Bressac-de Paillerets B
    Genes Chromosomes Cancer; 2007 Aug; 46(8):751-60. PubMed ID: 17492760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melanoma genetics: an update on risk-associated genes.
    Udayakumar D; Tsao H
    Hematol Oncol Clin North Am; 2009 Jun; 23(3):415-29, vii. PubMed ID: 19464594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic testing for hereditary melanoma and pancreatic cancer: a longitudinal study of psychological outcome.
    Aspinwall LG; Taber JM; Leaf SL; Kohlmann W; Leachman SA
    Psychooncology; 2013 Feb; 22(2):276-89. PubMed ID: 23382133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.